Krankheitskosten bei Alzheimer-Demenz

Kiencke, P.; Rychlik, Reinhard; Grimm, Christine; Daniel, D.

doi:10.1007/s00063-010-1060-4

Cited by 9 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on previous studies, we expected a different degree of ADL dependency for individuals in each setting [12,17,18] and regarded an unequal care level distribution as a potential source of bias. For a comprehensive comparison, we therefore further stratified both populations according to care level, using the care level assigned on 30 June as the classification criterion.…”

Section: Methodsmentioning

confidence: 99%

Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data

Schwarzkopf

Menn

Leidl

et al. 2013

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundDementia patients are often cared for in institutional arrangements, which are associated with substantial spending on professional long-term care services. Nevertheless, there is little evidence on the exact cost differences between community-based and institutional dementia care, especially when it comes to the distinct health care services. Adopting the perspective of the German social security system, which combines Statutory Health Insurance and Compulsory Long-Term Care Insurance (payer perspective), our study aimed to compare community-living and institutionalized dementia patients regarding their health care service utilization profiles and to contrast the respective expenditures.MethodsWe analysed 2006 claims data for 2,934 institutionalized and 5,484 community-living individuals stratified by so-called care levels, which reflect different needs for support in activities of daily living. Concordant general linear models adjusting for clinical and demographic differences were run for each stratum separately to estimate mean per capita utilization and expenditures in both settings. Subsequently, spending for the community-living and the institutionalized population as a whole was compared within an extended overall model.ResultsRegarding both settings, health and long-term care expenditures rose the higher the care level. Thus, long-term care spending was always increased in nursing homes, but health care spending was comparable. However, the underlying service utilization profiles differed, with nursing home residents receiving more frequent visits from medical specialists but fewer in-hospital services and anti-dementia drug prescriptions. Altogether, institutional care required additional yearly per capita expenses of ca. €200 on health and ca. €11,200 on long-term care.ConclusionCommunity-based dementia care is cost saving from the payer perspective due to substantially lower long-term care expenditures. Health care spending is comparable but community-living and institutionalized individuals present characteristic service utilization patterns. This apparently reflects the existence of setting-specific care strategies. However, the bare economic figures do not indicate whether these different concepts affect the quality of care provision and disregard patient preferences and caregiver-related aspects. Hence, additional research combining primary and secondary data seems to be required to foster both, sound allocation of scarce resources and the development of patient-centred dementia care in each setting.

show abstract

Section: Methodsmentioning

confidence: 99%

Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data

Schwarzkopf

Menn

Leidl

et al. 2013

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…8 Studies with data from statutory health insurance calculated dementia-related costs to range between €586 and €1129 per month. 9,10 Other European studies found that total costs were between €507 and €2411 (mild) and €881 and €4579 (severe). 5,8 A recent study on the determinants of the societal costs (total costs for the society) of DAT listed the cost predictors from several studies, 11 to which we added the latest references (see Table S1 in supporting information).…”

Section: Introductionmentioning

confidence: 99%

“…For patients in long‐term care institutions, the costs were even higher, ranging from €5109 (mild) to €5311 (severe) 8 . Studies with data from statutory health insurance calculated dementia‐related costs to range between €586 and €1129 per month 9,10 . Other European studies found that total costs were between €507 and €2411 (mild) and €881 and €4579 (severe) 5,8 …”

Section: Introductionmentioning

confidence: 99%

Apathy in patients with Alzheimer's disease is a cost‐driving factor

Kruse

Maier

Spottke

et al. 2023

Alzheimer's & Dementia

View full text Add to dashboard Cite

Background: Apathy is the most frequent neuropsychiatric symptom in patients with dementia of the Alzheimer's type (DAT). We analyzed the influence of apathy on the resource use of DAT patients and their caregivers.Methods: Included were baseline data of 107 DAT patients from a randomized clinical trial on apathy treatment. The Resource Utilization in Dementia (RUD) instrument assessed costs over a 1-month period prior to baseline. Cost predictors were determined via a least absolute shrinkage and selection operator (LASSO).Results: On average, total monthly costs were €3070, of which €2711 accounted for caregivers' and €359 for patients' costs. An increase of one point in the Apathy Evaluation Scale resulted in a 4.1% increase in total costs.

show abstract

“…Die Ergebnisse zeigen, dass Verzicht auf Antidementiva besonders in der Pflege mit höheren Kosten verbunden ist. Die niedrigsten Kosten finden sich trotz relativ hoher Arzneimittelkosten in der Gruppe, die medikamentös behandelt wurde [33]. Eine Beschränkung auf die Kostenträgerperspektive GKV greift hier definitiv zu kurz.…”

Section: Integrationsaspekte: Vermeidung Von Pflegekosten Bei Alzheimunclassified

Arzneimittelbewertung post AMNOG – Grenzen der Nutzenreflexion durch die Trennung von Kranken- und Pflegeversicherung am Beispiel der Demenz

Ulrich¹,

Maier²

2014

Gesundh ökon Qual manag

View full text Add to dashboard Cite

Zusammenfassung Die im Zusammenhang mit dem AMNOG in Kraft getretenen Neuregelungen im Bereich der Versorgung mit Arzneimitteln sowie deren Erstattung durch die Krankenversicherung f?hren insbesondere an der Sektorengrenze zwischen Kranken- und Pflegeversicherung zu Verwerfungen. Eine Nutzenbewertung aus st?rker integrierter Sozialversicherungsperspektive stellt eine M?glichkeit zur ?berwindung der damit einhergehenden Fehlanreize dar.

show abstract

Krankheitskosten bei Alzheimer-Demenz

Abstract: The results demonstrate that non-antidementive therapy for Alzheimer's disease causes higher costs especially in nursing care. The memantine group proved superior even though it had the highest costs in the specific drug category.

Cited by 9 publications

References 5 publications

Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data

Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data

Apathy in patients with Alzheimer's disease is a cost‐driving factor

Arzneimittelbewertung post AMNOG – Grenzen der Nutzenreflexion durch die Trennung von Kranken- und Pflegeversicherung am Beispiel der Demenz

Contact Info

Product

Resources

About